The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]


Variant: NM_000162.5(GCK):c.1181G>T (p.Arg394Leu)

CA367398578

1522625 (ClinVar)

Gene: GCK
Condition: monogenic diabetes
Inheritance Mode: Semidominant inheritance
UUID: 7b717baa-5df4-4bbc-8132-edfcceb7b495

HGVS expressions

NM_000162.5:c.1181G>T
NM_000162.5(GCK):c.1181G>T (p.Arg394Leu)
NC_000007.14:g.44145569C>A
CM000669.2:g.44145569C>A
NC_000007.13:g.44185168C>A
CM000669.1:g.44185168C>A
NC_000007.12:g.44151693C>A
NG_008847.1:g.48855G>T
NG_008847.2:g.57602G>T
ENST00000395796.8:c.*1179G>T
ENST00000616242.5:c.*301G>T
ENST00000683378.1:n.407G>T
ENST00000336642.9:c.215G>T
ENST00000345378.7:c.1184G>T
ENST00000403799.8:c.1181G>T
ENST00000671824.1:c.1244G>T
ENST00000672743.1:n.193G>T
ENST00000673284.1:c.1181G>T
ENST00000336642.8:n.233G>T
ENST00000345378.6:c.1184G>T
ENST00000395796.7:c.1178G>T
ENST00000403799.7:c.1181G>T
ENST00000437084.1:c.1130G>T
ENST00000459642.1:n.561G>T
ENST00000616242.4:n.1178G>T
NM_000162.3:c.1181G>T
NM_033507.1:c.1184G>T
NM_033508.1:c.1178G>T
NM_000162.4:c.1181G>T
NM_001354800.1:c.1181G>T
NM_001354801.1:c.170G>T
NM_001354802.1:c.41G>T
NM_001354803.1:c.215G>T
NM_033507.2:c.1184G>T
NM_033508.2:c.1178G>T
NM_033507.3:c.1184G>T
NM_033508.3:c.1178G>T
NM_001354803.2:c.215G>T

Uncertain Significance

Met criteria codes 4
PP3 PP2 PP4_Moderate PM2_Supporting

Evidence Links 0

Expert Panel

Criteria Specification Information

Criteria Specification: ClinGen Monogenic Diabetes Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for GCK Version 1.2.0

Criteria Specification Approval History
Criteria Specifications for this VCEP
Evidence submitted by expert panel
Monogenic Diabetes VCEP
The c.1181G>T variant in the glucokinase gene, GCK, causes an amino acid change of arginine to leucine at codon 394 (p.(Arg394Leu)) of transcript NM_000162.5. This variant is absent from gnomAD v2.1.1 (PM2_Supporting). GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2). This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.925 which is greater than the MDEP VCEP threshold of 0.70 (PP3). This variant was identified in an individual with a clinical history highly specific for GCK-MODY (FBG 5.5-8 mmol/L and HbA1c 5.6 - 7.6% and three generation family history of diabetes/hyperglycemia) (PP4_Moderate; internal lab contributors). In summary, c.1181G>T meets the criteria to be classified as uncertain significance for monogenic diabetes. ACMG/AMP criteria applied, as specified by the ClinGen MDEP (specification version 1.2.0 approved 6/7/2023): PM2_Supporting, PP2, PP3, PP4_Moderate.
Met criteria codes
PP3
This variant is predicted to be deleterious by computational evidence, with a REVEL score of 0.801, which is greater than or equal to the MDEP VCEP threshold of 0.70 (PP3).
PP2
GCK is defined by the ClinGen MDEP as a gene that has a low rate of benign missense variation and has pathogenic missense variants as a common mechanism of disease (PP2).
PP4_Moderate
This variant was identified in an individual with a clinical history highly specific for GCK-MODY (FBG 5.5-8 mmol/L, HbA1c 5.6 - 7.6%, and three generation family history of diabetes/hyperglycemia) (PP4_Moderate; internal lab contributors).
PM2_Supporting
This variant is absent from gnomAD v2.1.1 (PM2_Supporting).
Approved on: 2023-07-16
Published on: 2023-07-16
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.